RxDoctor Payments Data

Geetika Sabharwal, MD

Allergy & Immunology · Bradenton, FLNPI 1457581290

Payments from drug & device makers

$5,220in general payments, 2019–2025

Across 170 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$812
  • GSK$809
  • Regeneron Healthcare Solutions, Inc.$411
  • CSL Behring$253
  • Takeda Pharmaceuticals U.S.A., Inc.$221
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$230%
  • Food & beverage$4,97295%
  • Education$2254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,220 in reported general payments places this provider in the 45th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$439,620
Medicare patients
307
Services billed
20,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab16$99,043
XolairOmalizumab13$64,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$31,218
Breo ElliptaFluticasone/Vilanterol39$17,367
Spiriva RespimatTiotropium Bromide25$13,711
Advair HfaFluticasone Propion/Salmeterol20$7,893
Epinephrine15$3,918
Azelastine Hcl75$1,811
Fluticasone Propionate102$1,090
Montelukast Sodium84$985
Levocetirizine Dihydrochloride60$869
Ipratropium Bromide32$723
Albuterol Sulfate HfaAlbuterol Sulfate38$704
Famotidine47$398
Triamcinolone Acetonide19$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$50$64,11813 claims
GSKTrelegy Ellipta, Breo Ellipta$809$48,58581 claims
Boehringer IngelheimSpiriva Respimat$24$13,71125 claims
Hikma Pharmaceuticals USAEpinephrine$50$3,91815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →